8-K: Earth Science Tech Reports Stellar Fiscal Year 2025 Results with Revenue Tripling to Over $33 Million and Net Profit Soaring

Earth Science Tech, Inc. announced robust financial performance for the fiscal year ended March 31, 2025, reporting a 177.05% increase in revenue to $33.1 million and a 300.63% surge in net profit to $3.2 million.

Summary

• For the fiscal year ended March 31, 2025, revenue reached $33,117,624, marking a 177.05% increase from $11,953,635 in the prior fiscal year.
• Net Profit for the fiscal year ended March 31, 2025, was $3,253,635, representing a 300.63% increase from $812,139 in the previous fiscal year.
• Cash increased by 111.15% year-over-year to $1,473,228 as of March 31, 2025, up from $697,721 as of March 31, 2024.
• Total Assets grew by 82.07% year-over-year to $7,066,721 as of March 31, 2025, compared to $3,881,336 as of March 31, 2024.
• Gross Profit for the fiscal year ended March 31, 2025, was $24,300,136, an increase of 210.41% from $7,828,496 in the prior fiscal year.
• Outstanding Shares decreased by 4.72% to 295,347,903 as of March 31, 2025, down from 309,981,819 as of March 31, 2024.
• The company operates as a strategic holding company focused on value creation through acquisition, operational optimization, and management of its operating businesses, which include compounding pharmaceuticals, telemedicine, and real estate development.
• Subsequent to the reporting period, the company acquired 100% of Las Villas Health Care, Inc., DOConsultations, LLC, and an 80% interest in MagneChef.
• Mister Meds, acquired on October 1, 2024, received full compounding licensure in March 2025.
• Avenvi, a diversified real estate company, manages investment activities for the company and oversees its ongoing $5 million share repurchase program.

Sentiment

Score: 9

Explanation: The company reported exceptional year-over-year growth across all key financial metrics, including revenue, net profit, cash, and total assets, coupled with a reduction in outstanding shares and successful strategic acquisitions. This indicates strong operational performance and financial health.

Positives

• Revenue increased by 177.05% year-over-year to $33,117,624.
• Net Profit surged by 300.63% year-over-year to $3,253,635.
• Cash position improved by 111.15% year-over-year to $1,473,228.
• Total Assets grew by 82.07% year-over-year to $7,066,721.
• Gross Profit increased by 210.41% year-over-year to $24,300,136.
• Outstanding shares were reduced by 4.72%, indicating a more favorable share structure.
• Successful strategic acquisitions including Mister Meds, Las Villas Health Care, DOConsultations, MagneChef, and Zoolzy.com, expanding operational scope.
• Mister Meds pharmacy achieved full compounding licensure in March 2025, enhancing service capabilities.
• An ongoing $5 million share repurchase program is in place, managed by Avenvi.
• The company successfully recovered from a challenging period, clearing all debt by December 2023 after being near bankruptcy in September 2022.
• Employee count across all subsidiaries increased from 36 to 76 year-over-year, reflecting business expansion.

Risks

• The markets for the company's products and services are subject to risks and uncertainties.
• Costs of goods and services may fluctuate, impacting financial results.
• Other expenses could vary, affecting profitability.
• Government regulations may change, potentially impacting operations and financial performance.
• Litigations pose a potential risk to the company's operations and financial stability.
• General business conditions could adversely affect the company's performance.
• Forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from current expectations.

Future Outlook

The company's telemedicine platform, Peaks, aims to offer services nationwide through the development of its own healthcare provider network and ongoing licensure expansion for its pharmacies. MagneChef is in the process of expanding its product line to include new offerings that incorporate its intellectual property.

Management Comments

• Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses.

Industry Context

Earth Science Tech operates as a strategic holding company with a strong focus on the healthcare sector, specifically compounding pharmaceuticals and telemedicine, complemented by real estate development. The significant growth in revenue and net profit, coupled with strategic acquisitions like Mister Meds, Las Villas Health Care, DOConsultations, and expansion into the veterinary market via Zoolzy.com, indicates a successful execution of its diversification and growth strategy within specialized healthcare services. The company's ability to clear prior debt and implement a share repurchase program suggests robust financial management and a strong position within its niche markets, potentially outperforming smaller, less diversified competitors in the compounding pharmacy and telemedicine space.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or industry benchmarks to assess the results against.

Management Changes

Corporate Governance

Related Party Transactions

• The company acquired RxCompoundStore.com and Peaks Curative from Mario Guillermo Tabraue (current COO) via a debt note.
• Giorgio R. Saumat (current CEO and Chairman) provided a $350,000 convertible note and secured conversion of all partner debts to equity during the company's recovery phase.

Stakeholder Impact

• Shareholders: Positively impacted by significant financial growth, increased profitability, a share repurchase program, and a reduction in outstanding shares, indicating enhanced shareholder value.
• Employees: Positively impacted by the increase in employee count from 36 to 76, reflecting business expansion and job creation.
• Customers: Positively impacted by the expansion of services, including increased state licensure for pharmacies, the development of a telemedicine platform, and the acquisition of new healthcare facilities like Las Villas Health Care, offering broader access to services.
• Creditors: Positively impacted as the company cleared all debt by December 2023, demonstrating improved financial health and reduced credit risk.
• Suppliers: Potentially positively impacted due to increased operational scale and demand for goods and services from the company's growing subsidiaries.

Next Steps

• RxCompound is actively pursuing licensure in the remaining U.S. states to expand its service reach.
• Mister Meds is currently applying for licensure in states not yet serviced by RxCompound to further expand its operational footprint.
• Peaks aims to offer services nationwide through the development of its own healthcare provider network, MyOnlineConsultation.com, and ongoing licensure expansion for both RxCompound and Mister Meds.
• MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property.
• Avenvi will continue to oversee the company's ongoing $5 million share repurchase program.

Key Dates

Recommendation

Keywords

Earth Science Tech, ETST, financial results, fiscal year 2025, revenue growth, net profit, compounding pharmacy, telemedicine, real estate development, strategic holding company, share repurchase, acquisitions, RxCompoundStore, Peaks Curative, Mister Meds, Avenvi, Las Villas Health Care, DOConsultations, MagneChef